TY - JOUR
T1 - Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India
T2 - Potential Avenues for Vaccine Design
AU - Hussain, Syed Iqbal
AU - Panneerselvam, Nandagopal
AU - Solomon, Suniti
AU - Solomon, Sunil S.
AU - Adam, Kaavya
AU - Chandrasekaran, Ezhilarasi
AU - Montefiori, David C.
AU - Pachamuthu, Balakrishnan
N1 - Publisher Copyright:
© SAGE Publications.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Identification of broadly neutralizing antibodies (NAbs) generated during the course of HIV-1 infection is essential for effective HIV-1 vaccine design. The magnitude and breadth of neutralizing activity in the sera from 46 antiretroviral treatment-naive HIV-1 clade C-infected individuals was measured in a single round infection assay using TZM-bl cells and multisubtype panel of env-pseudotyped viruses. Higher levels of NAb response (NAb titer 500 to >40 000) were measured in these patients against tier 1 and tier 2 viruses. The average magnitude of the NAb responses of chronically infected individuals against heterologous viruses was consistently higher than the response observed from individuals with long-term nonprogressor (P =.086). To conclude, high titers of HIV-1 cross-neutralizing activity were observed in the sera from a subset of HIV-1-infected individuals in Chennai, India. Additional studies of the epitopes recognized by these antibodies may facilitate the discovery of an effective vaccine immunogen.
AB - Identification of broadly neutralizing antibodies (NAbs) generated during the course of HIV-1 infection is essential for effective HIV-1 vaccine design. The magnitude and breadth of neutralizing activity in the sera from 46 antiretroviral treatment-naive HIV-1 clade C-infected individuals was measured in a single round infection assay using TZM-bl cells and multisubtype panel of env-pseudotyped viruses. Higher levels of NAb response (NAb titer 500 to >40 000) were measured in these patients against tier 1 and tier 2 viruses. The average magnitude of the NAb responses of chronically infected individuals against heterologous viruses was consistently higher than the response observed from individuals with long-term nonprogressor (P =.086). To conclude, high titers of HIV-1 cross-neutralizing activity were observed in the sera from a subset of HIV-1-infected individuals in Chennai, India. Additional studies of the epitopes recognized by these antibodies may facilitate the discovery of an effective vaccine immunogen.
KW - HIV-1 neutralization assay
KW - HIV-1 pseudoviruses
KW - LTNP
KW - humoral response
UR - http://www.scopus.com/inward/record.url?scp=85016101893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016101893&partnerID=8YFLogxK
U2 - 10.1177/1545109712467695
DO - 10.1177/1545109712467695
M3 - Article
C2 - 23422744
AN - SCOPUS:85016101893
VL - 16
SP - 201
EP - 208
JO - Journal of the International Association of Providers of AIDS Care
JF - Journal of the International Association of Providers of AIDS Care
SN - 2325-9574
IS - 2
ER -